Berinert denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for berinert are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BlueCross BlueShield May Deny Berinert as "Experimental or Investigational"

Berinert is an FDA-approved plasma-derived C1 esterase inhibitor (C1-INH) concentrate indicated for acute treatment of hereditary angioedema (HAE) attacks. An "experimental or investigational" denial from BCBS is surprising given its approval status, but it can occur when the specific clinical context falls outside the labeled indication — for example, when Berinert is used for a non-hereditary angioedema indication, in a patient population not addressed by the label, or for a prophylactic purpose rather than acute treatment. It can also occur when BCBS's Medical Policy has not been updated to reflect the current label, or when a claims coding issue causes the system to flag the claim incorrectly. This denial is among the most legally vulnerable: insurers must base experimental denials on a rigorous, evidence-based review, and Berinert's FDA approval provides a strong rebuttal.

## Your Appeal Rights

Under ACA Section 2719 and ERISA Section 503, you have the right to a full-and-fair internal appeal followed by independent external review through an accredited IRO. File the external-review request within four months of the final adverse determination. HAE attacks can be life-threatening — expedited review (72-hour decision) is available and should be requested if there is any clinical urgency. For employer-sponsored plans, the external reviewer is required to apply independent evidence-based standards, not BCBS's internal policy.

## The Appeal Process

1. Request the denial letter and the BCBS Medical/Coverage Policy for Berinert; confirm exactly which criterion ("experimental," "investigational," or "not medically necessary for this indication") triggered the denial. 2. Obtain the current FDA-approved prescribing information for Berinert and confirm the specific indication under which it was prescribed. 3. File a Level 1 internal appeal with the FDA label and supporting specialist documentation. 4. If upheld, escalate immediately to external IRO — experimental denials are frequently overturned at the IRO level when FDA approval is clear. 5. Document your state's external-review law and cite it if applicable.

## Documentation to Gather

• FDA approval documentation: Print the current FDA-approved prescribing label for Berinert from the FDA website, highlighting the approved indication under which it was prescribed. This is the single most powerful document in this appeal.
• Diagnosis confirmation: Lab or genetic documentation confirming hereditary angioedema (C1-INH deficiency or dysfunction), establishing that the use is within the approved indication.
• HAE specialist letter: A letter from the treating allergist, immunologist, or HAE specialist confirming the FDA-approved indication, explaining that Berinert is the established standard of care for this condition, and citing the applicable HAEA or international HAE guideline.
• BCBS policy review: Identify whether BCBS's Medical Policy is out of date relative to the FDA label or specialty-society guidance, and document that discrepancy explicitly in the appeal letter.
• Attack severity records: Documentation of attack frequency, severity, and affected body regions to establish clinical necessity independent of the experimental classification argument.

## Criteria-Mapping Structure

| BCBS "Experimental" Criterion | Counter-Evidence | |---|---| | Not FDA-approved | Current FDA label with approved indication highlighted | | Lacks sufficient clinical evidence | HAE specialist letter citing established standard-of-care status | | Outside approved indication | Diagnosis documentation matching label indication precisely | | Policy basis for experimental classification | BCBS policy text vs. FDA label — identify any gap or outdated criteria |

When FDA approval is unambiguous and the clinical use matches the label, an experimental denial is among the strongest appeal scenarios available.